XML 59 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
DESCRIPTION OF BUSINESS (Details)
$ in Thousands, shares in Millions
1 Months Ended 12 Months Ended
Sep. 30, 2016
USD ($)
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Apr. 30, 2018
patient
Variable Interest Entity [Line Items]          
Number of patients | patient         133
Cash and cash equivalents   $ 162,636 $ 52,389 $ 48,121  
Accumulated deficit   316,257 315,921    
Negative cash flows from operating activities incurred   $ 68,878 $ 30,837 $ 37,521  
Viventia Bio Inc.          
Variable Interest Entity [Line Items]          
Shares of common stock issued to the selling shareholders (in shares) | shares 4.0        
Percentage of voting interests acquired 19.90%        
Period during which quarterly earn-outs are payable after date of net sales 15 years        
Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations 7 years        
Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone          
Variable Interest Entity [Line Items]          
Percentage of net sales of quarterly earn-out payments during earn-out periods 2.00%        
Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | United States          
Variable Interest Entity [Line Items]          
One-time milestone payment upon first sale of product $ 12,500        
Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Europe          
Variable Interest Entity [Line Items]          
One-time milestone payment upon first sale of product 7,000        
Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Japan          
Variable Interest Entity [Line Items]          
One-time milestone payment upon first sale of product $ 3,000